Genmab (Otc) ((GMAB)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab is conducting a Phase 1/2 clinical study titled ‘A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors.’ The study aims to assess the safety, tolerability, pharmacokinetics, anti-tumor activity, and immunogenic potential of the drug GEN1286 in patients with advanced solid tumors. This research is significant as it could lead to new treatment options for patients with limited alternatives.
The intervention being tested is GEN1286, a drug designed to treat advanced solid tumors. The study will evaluate different doses to determine the most effective and safe dosage for patients.
The study follows an interventional design with a sequential intervention model. In Part A, dose escalation occurs without randomization, while Part B involves tumor-specific expansion with randomization in a 1:1 ratio. The primary purpose of the study is treatment-focused, with no masking involved.
The study began on November 13, 2024, with the primary completion and estimated completion dates yet to be announced. The most recent update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study update could influence Genmab’s stock performance positively if the results show promise, as successful trials often boost investor confidence. It also positions Genmab competitively within the oncology sector, where advancements are highly valued.
The study is ongoing, with further details available on the ClinicalTrials portal.